LONDON — An expert group that the World Health Organization tasked with investigating how the COVID-19 pandemic started ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron acquires rights to HS-20094, a promising obesity treatment from Hansoh Pharma, enhancing its metabolic programs.

Regeneron is paying Hansoh $80 million upfront for a phase 3-stage GLP-1/GIP agonist the companies believe can hold its own against Lilly’s Zepbound.

Federal Circuit decision in appeal from Regeneron Pharms., Inc. addresses issues of personal jurisdiction, preliminary injunctions, and biopharmaceutical patent vali ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.